Qiuyan Song1, Yuanxuan Cai2, Kangyuan Guo3, Min Li4, Zaoqin Yu4, Qirui Tai1, Yuhang Zhao2, Xuan Zhu5, Chengliang Zhang4. 1. Department of Pharmacy, The Sixth Affiliated Hospital of Kunming Medical University Yuxi 653100, Yunnan, China. 2. School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China. 3. School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China. 4. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China. 5. School of Computer, Central China Normal University Wuhan 430079, Hubei, China.
Abstract
OBJECTIVE: Hypersensitivity reactions with oxaliplatin (OXA) have attracted much attention. This study aimed to analyze the risk factors for OXA-induced hypersensitivity reaction in Chinese colorectal cancer patients through a single-center retrospective investigation. METHODS: The information from 459 colorectal cancer patients treated with OXA in a hospital was collected retrospectively to explore the risk factors for OXA-induced hypersensitivity reaction. RESULTS: Among the 459 patients, 47 (10.24% incidence) cases developed hypersensitivity reactions, with a 3.70% incidence of grade III/IV reaction. The main symptoms included itching, flushing, dyspnea, and rash, which mainly involved skin and adnexa, respiratory system, and nervous system. Dexamethasone pretreatment presented no significant effects on the hypersensitivity reaction (P = 0.282). Multivariate analysis indicated that the previous allergic history (odds ratio (OR) 2.553, 95% confidence interval (CI) 1.139-5.721, P = 0.023) and OXA-free interval (OR 3.605, 95% CI 1.909-6.809, P = 0.000) were independent risk factors for OXA-induced hypersensitivity reaction. CONCLUSIONS: The incidence of OXA-induced hypersensitivity reaction in colorectal cancer patients was similar to those reported in other countries. Clinical medical staff should pay close attention to high-risk factors, such as allergic history and patients having OXA-free intervals in order to avoid or alleviate hypersensitivity reactions. AJTR
OBJECTIVE: Hypersensitivity reactions with oxaliplatin (OXA) have attracted much attention. This study aimed to analyze the risk factors for OXA-induced hypersensitivity reaction in Chinese colorectal cancer patients through a single-center retrospective investigation. METHODS: The information from 459 colorectal cancer patients treated with OXA in a hospital was collected retrospectively to explore the risk factors for OXA-induced hypersensitivity reaction. RESULTS: Among the 459 patients, 47 (10.24% incidence) cases developed hypersensitivity reactions, with a 3.70% incidence of grade III/IV reaction. The main symptoms included itching, flushing, dyspnea, and rash, which mainly involved skin and adnexa, respiratory system, and nervous system. Dexamethasone pretreatment presented no significant effects on the hypersensitivity reaction (P = 0.282). Multivariate analysis indicated that the previous allergic history (odds ratio (OR) 2.553, 95% confidence interval (CI) 1.139-5.721, P = 0.023) and OXA-free interval (OR 3.605, 95% CI 1.909-6.809, P = 0.000) were independent risk factors for OXA-induced hypersensitivity reaction. CONCLUSIONS: The incidence of OXA-induced hypersensitivity reaction in colorectal cancer patients was similar to those reported in other countries. Clinical medical staff should pay close attention to high-risk factors, such as allergic history and patients having OXA-free intervals in order to avoid or alleviate hypersensitivity reactions. AJTR
Authors: D Santini; G Tonini; A Salerno; B Vincenzi; G Patti; F Battistoni; G Dicuonzo; R Labianca Journal: Ann Oncol Date: 2001-01 Impact factor: 32.976
Authors: Georg Lenz; Ulrich T Hacker; Wolfgang Kern; Andreas Schalhorn; Wolfgang Hiddemann Journal: Anticancer Drugs Date: 2003-10 Impact factor: 2.248
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: A Polyzos; N Tsavaris; C Kosmas; T Arnaouti; N Kalahanis; C Tsigris; A Giannopoulos; G Karatzas; L Giannikos; P P Sfikakis Journal: Oncology Date: 2001 Impact factor: 2.935
Authors: G Brandi; M A Pantaleo; C Galli; A Falcone; A Antonuzzo; P Mordenti; M C Di Marco; G Biasco Journal: Br J Cancer Date: 2003-08-04 Impact factor: 7.640